Tempus AI shares surge 30% as Morgan Stanley flags reimbursement revenue lift for xT and xF diagnostics
Reimbursement pricing clarity for AI diagnostics rarely moves a stock by 30% in a week. After Morgan Stanley on September 15 drew attention to how newly defined pricing on Tempus AI's (NASDAQ: TEM) xT and xF products could add…
Key takeaways
- Tempus AI (NASDAQ: TEM) shares rose roughly 30% over five sessions after Morgan Stanley on September 15 highlighted new pricing on its xT and xF diagnostics.
- Morgan Stanley estimated the newly defined pricing could add between $330 million and $400 million in combined annual revenue.
- CEO Eric Lefkofsky said xT pricing could add $80 million to $100 million next year and xF could add $250 million to $300 million annually.
- In Q2 FY2026 Tempus reported $382.49 million in revenue, up 21.6% year over year, with oncology testing volumes accelerating 31%.
- Tempus raised full-year guidance to between $1.595 billion and $1.605 billion, with adjusted EBITDA guidance of about $65 million.
Reimbursement pricing clarity for AI diagnostics rarely moves a stock by 30% in a week. After Morgan Stanley on September 15 drew attention to how newly defined pricing on Tempus AI's (NASDAQ: TEM) xT and xF products could add between $330 million and $400 million in combined annual revenue, shares gained roughly 30% over five sessions, including a 13.83% move on Thursday that took the stock to $79.65.
What the reimbursement numbers imply
CEO Eric Lefkofsky said xT pricing could add $80 million to $100 million in revenue next year, with xF approval and pricing potentially adding $250 million to $300 million annually. Both figures align with management's prior guidance of approximately $400 million in revenue uplift by 2028 across the XT CDx and XF approvals. Lefkofsky also indicated the company should over-deliver on its stated 25% multiyear growth target.
The Q2 FY2026 result provides the operational backdrop. The Chicago-based precision medicine platform reported $382.49 million in revenue, up 21.6% year over year, with oncology testing volumes accelerating 31%. Full-year guidance was raised to between $1.595 billion and $1.605 billion, and adjusted EBITDA guidance stands at approximately $65 million. Market capitalization sits near $14.0 billion.
The data licensing book and who it touches
The data and applications segment adds a separate growth line. Tempus booked approximately $200 million in data licensing in Q2, drawing on a customer roster that includes AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Daiichi Sankyo, Levelset Bio, and Insight Pharmaceuticals. Lefkofsky described the segment in plain terms: "The data business is just on fire." That customer roster, sector-wide, reads as a demand environment with pharmaceutical backing that extends across multiple development pipelines.
The analyst picture carries the macro caveat. Forward EPS estimates for fiscal 2027 moved from negative $0.1067 ninety days ago to $0.0040 today, with eight upward revisions over the past 30 days, and the FY2027 revenue consensus sits at $1.97 billion. The stock trades at roughly 9x sales. Despite a 54.24% one-month gain, TEM remains below its 52-week high of $104.32, and the consensus analyst target of $68.18 now trails the market price. The stock carries a beta of 3.7, GAAP losses continue, and stock-based compensation totaled $54.1 million in Q2. The pending Personalis deal would add a minimal residual disease platform in what management has framed as a $20 billion-plus market opportunity, extending the timeline before free cash flow turns positive.
Related reading
Source · 來源